HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
CyQ3phDApMyZM7VX